TNFSF10

TNFSF10 (TRAIL) is a TNF-superfamily death ligand that engages cell-surface death receptors to trigger caspase-dependent apoptosis and a broader set of regulated cell-death and inflammatory programs (PMID:9082980, PMID:9311998). It binds two distinct death-domain-containing receptors: DR4/TRAIL-R1, which initially appeared to transmit death signals through machinery distinct from FADD, and TRAIL-R2/DR5, which recruits the adaptor FADD/MORT1 to assemble a death-inducing signaling complex (DISC) with procaspase-8 (PMID:9082980, PMID:9311998, PMID:12761581). DISC assembly and apoptotic output are tunable: N-linked glycosylation of TRAIL-R1 enhances receptor aggregation and DISC formation without altering ligand affinity (PMID:28186505), receptor-selective TRAIL variants reveal that some primary tumors signal almost exclusively through TRAIL-R1 (PMID:16357130), and co-engagement of TRAIL-R2 by ligand plus the agonist antibody AMG655 synergistically amplifies DISC formation and killing (PMID:24909167). TRAIL also drives non-apoptotic outcomes through the same receptors—cytoprotective autophagy via TRAF2/RIPK1-MAPK8/JNK signaling that degrades BCL2L1 and via PARP1-dependent HMGB1-BECN1 complex formation (PMID:23051914, PMID:25607248), necroptosis dependent on sphingomyelinases and HtrA2/Omi (PMID:25299769, PMID:27528614), and entosis that diverges from apoptosis at caspase-8 (PMID:34546352)—with TRAF2 and PRMT5 acting as negative regulators that restrain death signaling and promote NF-κB-driven resistance (PMID:19372584, PMID:25299769). TRAIL expression is transcriptionally controlled: it is a direct p53 target gene through promoter binding sites that mediate chemotherapy-induced apoptosis (PMID:19106633), and is induced by IFNγ in immune and tissue contexts, including IFNγ-driven astrocytes that limit CNS inflammation by inducing T-cell apoptosis through TRAIL-DR5 (PMID:33408417). Lineage-specific induction also governs roles in megakaryocyte differentiation, where autocrine TRAIL-TRAIL-R2 signaling regulates megakaryocytic output (PMID:15539085, PMID:15828026).

1. 1997 High

   Establishing the receptors through which TRAIL signals defined how an extracellular ligand engages the intracellular apoptotic apparatus, and revealed early evidence for receptor-specific signaling logic.

   Evidence Receptor identification by homology/database searching and ligand-based affinity purification, with death-domain and FADD-signaling characterization (DR4/TRAIL-R1 and TRAIL-R2/DR5)

   PMID:9082980 PMID:9311998

   Open questions at the time

   • The apparent FADD-independence of DR4 versus FADD-dependence of DR5 was not reconciled at the structural level
   • Stoichiometry of the receptor-FADD-procaspase-8 DISC was not resolved
2. 2003 Medium

   Dissecting DISC composition in sensitive versus resistant cells showed apoptotic output is not strictly caspase-8-dependent, implicating parallel pathways including sphingolipid signaling.

   Evidence DISC assay with dominant-negative FADD/caspase-8 overexpression, Bax activation assay, and sphingosine kinase inhibition in rhabdomyosarcoma cells

   PMID:12761581

   Open questions at the time

   • The molecular identity of the caspase-8-independent death effector was not established
   • Single-lab, single-tumor-type observation
3. 2005 High

   Receptor-selective TRAIL mutants demonstrated that individual tumors can depend on a single receptor, with direct therapeutic targeting implications.

   Evidence Synthesis of TRAIL-R1- and TRAIL-R2-selective mutants with selective binding and DISC formation assays in primary CLL and mantle cell lymphoma cells

   PMID:16357130

   Open questions at the time

   • Why these tumors favor TRAIL-R1 was not mechanistically explained
   • Receptor preference across broader tumor types was not surveyed
4. 2008 High

   Identifying TNFSF10 as a direct p53 target connected the apoptotic ligand to the canonical tumor-suppressor and chemotherapy response.

   Evidence Adenoviral p53 overexpression, TRAIL promoter-luciferase reporter with mapped binding sites, siRNA knockdown, and caspase activity assays in HCT116 cells

   PMID:19106633

   Open questions at the time

   • The relative contribution of p53-driven TRAIL versus other p53 apoptotic targets was not quantified
   • In vivo relevance to tumor regression was not tested here
5. 2009 Medium

   Discovery of PRMT5 as a selective death-receptor-binding protein revealed a built-in resistance mechanism coupling receptor engagement to NF-κB survival signaling.

   Evidence Proteomic screen, Co-IP showing selective DR4/DR5 (not TNFR1/Fas) binding, siRNA knockdown, and IKKβ rescue of NF-κB activity

   PMID:19372584

   Open questions at the time

   • Whether PRMT5 methyltransferase activity is required was not resolved
   • Structural basis of selective receptor binding unknown
   • Single-lab finding
6. 2012 High

   Mapping a TRAF2/RIPK1-MAPK8 axis showed TRAIL induces cytoprotective autophagy that antagonizes its own DISC formation, explaining a source of resistance.

   Evidence Pharmacological inhibitors and siRNA knockdown of TRAF2, RIPK1, MAPK8, BECN1, ATG7 with DISC formation readout

   PMID:23051914

   Open questions at the time

   • How autophagy physically suppresses DISC assembly was not defined
   • Single-lab finding
7. 2014 High

   TRAF2 was established as a negative regulator gating both apoptosis and RIP3-dependent necroptosis downstream of TRAIL, independent of autocrine TNF.

   Evidence siRNA knockdown of TRAF2 with zVAD-fmk, necrostatin-1, RIP3 transfection, and TNF blockade across keratinocytes and HeLa cells

   PMID:25299769

   Open questions at the time

   • The biochemical target through which TRAF2 restrains the DISC was not identified
   • Generality across cell types not fully mapped
8. 2014 Medium

   Combining TRAIL with an agonist TRAIL-R2 antibody showed DISC formation can be cooperatively amplified, providing a route to overcome resistance.

   Evidence DISC formation and apoptosis assays with non-tagged Apo2L/TRAIL plus AMG655 in cancer cell lines and primary ovarian cancer cells

   PMID:24909167

   Open questions at the time

   • The receptor cluster geometry enabling synergy was not structurally defined
   • Single-lab finding
9. 2015 Medium

   A PARP1-HMGB1 axis was shown to drive cytoprotective autophagy and TRAIL resistance, identifying a distinct druggable resistance node.

   Evidence PARP1 inhibitors and knockdown, HMGB1 localization, HMGB1-BECN1 Co-IP, and subcutaneous tumor models

   PMID:25607248

   Open questions at the time

   • How PARP1 is activated by TRAIL signaling was not established
   • Relationship to the TRAF2/RIPK1 autophagy axis not integrated
   • Single-lab finding
10. 2016 Medium

    Defining the effector requirements of TRAIL-mediated necroptosis distinguished it mechanistically from TNF necroptosis.

    Evidence Pharmacological and genetic perturbation of sphingomyelinases, HtrA2/Omi, Atg5, V-ATPase; receptor internalization and endosome acidification assays in Colo357 cells

    PMID:27528614

    Open questions at the time

    • How these effectors are assembled into a death-executing module was not resolved
    • Single-lab finding
11. 2016 High

    Hepatitis B virus X protein was shown to degrade DR5 via selective autophagy, demonstrating viral subversion of TRAIL death signaling.

    Evidence Co-IP, GST pulldown, LC3B knockdown, autophagy inhibition, tandem-fluorescent LC3B imaging, and patient liver tissue immunoblotting

    PMID:27740879

    Open questions at the time

    • Whether host autophagy receptors normally turn over DR5 was not addressed
    • Generality beyond HBV-infected hepatocytes unknown
12. 2017 High

    N-linked glycosylation of TRAIL-R1 was shown to control apoptotic competence by promoting receptor aggregation and DISC formation independent of ligand affinity, and to mediate viral immune evasion.

    Evidence N-glycosylation-defective mutagenesis with apoptosis, DISC, receptor aggregation, ligand affinity, and CMV UL141 binding assays

    PMID:28186505

    Open questions at the time

    • How glycosylation status varies across cell types to set sensitivity was not surveyed
    • Structural basis of glycan-driven aggregation not resolved
13. 2021 High

    TRAIL signaling was shown to trigger entosis as a caspase-8-gated alternative to apoptosis, expanding the death-modality repertoire and linking it to tumor prognosis.

    Evidence DR4/DR5 KO, caspase-8 structural mutants, Bax/Bak double KO, caspase inhibition, live imaging, and colorectal tumor analysis

    PMID:34546352

    Open questions at the time

    • What determines entosis versus apoptosis choice at the receptor level was not defined
    • Mechanism of caspase-8 scaffolding for entosis unresolved
14. 2021 High

    An IFNγ-NK-astrocyte axis placed TRAIL within a microbiome-licensed neuroimmune circuit that restrains CNS inflammation by killing T cells via DR5.

    Evidence Flow cytometry screening, scRNA-seq, in vivo CRISPR-Cas9 cell-specific perturbation, and T cell apoptosis assays in mice

    PMID:33408417

    Open questions at the time

    • The transcriptional repressors that silence astrocytic TRAIL during inflammation were not fully defined
    • Human relevance of this circuit not established

• How receptor compartmentalization, glycosylation, and adaptor/regulator stoichiometry collectively dictate the choice among apoptosis, necroptosis, entosis, and cytoprotective autophagy downstream of TRAIL remains unresolved.
• No unified model integrating the TRAF2/RIPK1, PRMT5, and PARP1-HMGB1 resistance nodes
• The structural determinants distinguishing DR4 from DR5 signaling outputs are not defined